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Edited by Robert BaroukiAbstract The present study demonstrates the expression of
hexose-6-phosphate dehydrogenase and 11b-hydroxysteroid
dehydrogenase type 1 in human neutrophils, and the presence
and activity of these enzymes in the microsomal fraction of the
cells. Their concerted action together with the previously de-
scribed glucose-6-phosphate transporter is responsible for corti-
sone–cortisol interconversion detected in human neutrophils.
Furthermore, the results suggest that luminal NADPH genera-
tion by the cortisol dehydrogenase activity of 11b-hydroxyster-
oid dehydrogenase type 1 prevents neutrophil apoptosis
provoked by the inhibition of the glucose-6-phosphate trans-
porter. In conclusion, the maintenance of the luminal NADPH
pool is an important antiapoptotic factor in neutrophil granulo-
cytes.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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The glucose 6-phosphate transporter (G6PT) of the endo-
plasmic reticulum (ER) allows the entry of the cytosolic metab-
olite glucose-6-phosphate (G6P) into the luminal space. G6P is
the substrate for at least two luminal enzymes: glucose-6-phos-
phatase (G6Pase) and hexose-6-phosphate dehydrogenase
(H6PDH). The activity of the former enzyme is crucial for
the maintenance of blood glucose level [1,2]. Recent evidence
show that H6PDH has a role in regulating the redox state of
an ER pool of pyridine nucleotides, as well as in supplying
the cofactor NADPH to 11b-hydroxysteroid dehydrogenase
type 1 (11b-HSD1) [3–7]. This enzyme, highly represented in
liver and adipose tissue, is located within the ER lumen and
plays a key role in the prereceptorial activation of glucocorti-
coids [8–10].*Corresponding author. Address: Dipartimento di Fisiopatologia e,
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doi:10.1016/j.febslet.2008.04.045The genetic deﬁciency of G6PT, named glycogen storage dis-
ease type 1b (GSD 1b), causes – in addition to an inventory of
symptoms ultimately due to the lack of G6Pase activity – a se-
vere pathology of neutrophils/monocytes [11–14]. A recent re-
port shows that G6PT knock-out mice also present with
defects of neutrophils/monocytes largely mimicking those of
GSD 1b patients, such as alterations of cell diﬀerentiation
and growth, neutropenia, impairment of superoxide anion gen-
eration and chemotaxis [12]. We have previously observed that
the chemical ablation of G6PT activity (with the selective inhib-
itor S3483) [15,16] results in an impaired diﬀerentiation of the
promyelocytic HL-60 cell line, as well as in apoptosis of diﬀer-
entiated HL-60 cells and human neutrophils (PMNs) [17]. Con-
sistently, other authors observed that apoptotic PMNs are
present in the peripheral blood of GSD 1b patients [18].
In our aforementioned study [17] it was also observed that
the PMN apoptosis induced by S3483 is fully prevented by
the antioxidant vitamin E analogue, trolox C, as well as by
the inhibitor of NADPH oxidase, diphenylene iodonium. On
this ground, we hypothesized that G6P entry into the ER com-
partment mediated by G6PT might be required for the suﬃ-
cient antioxidant protection of PMNs. The G6PT-dependent
H6PDH activity in other tissues (i) keeps luminal pyridine
nucleotides in reduced state and (ii) allows the reductase activ-
ity of 11b-HSD1. However, neither H6PDH nor 11b-HSD1
has been reported to be present and functional in the neutro-
phil ER. Therefore, experiments were undertaken to investi-
gate the expression and activity of these enzymes in the ER
of human PMNs, with special emphasis on the possibility of
modulating neutrophil apoptosis through their activity.2. Materials and methods
2.1. Preparation of human PMNs
Human PMN cells of healthy volunteers were isolated from periph-
eral venous blood collected in tubes containing 16 IU heparin/ml
blood. The neutrophils were separated by dextran sedimentation meth-
od according to Hjorth et al. [19] with small modiﬁcations as described
in details earlier [17]. Preparations contained more than 95% PMNs
and cell viability (evaluated by trypan blue exclusion method) exceeded
97%.
2.2. Preparation of microsomal fractions
Microsomes from PMNs and rat liver were prepared as previously
reported [17]. Human liver microsomes were prepared as detailed
earlier [20]. The Ethical Committee of the Semmelweis Universityblished by Elsevier B.V. All rights reserved.
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mens. Microsomes were resuspended in MOPS-KCl buﬀer (100 mM
KCl, 20 mMNaCl, 1 mMMgCl2 and 20 mMMOPS) pH 7.2 including
a cocktail of protease inhibitors, and maintained under liquid N2 until
used. Immediately before Western blot analysis or enzyme assay, the
possible cytosolic or other contaminants loosely associated with the
vesicles were removed by a rapid washing as follows: polyethylene gly-
col (at 7% w/v ﬁnal concentration) was added to the microsomes and
the suspension was centrifuged at 4000 · g for 15 s. After discarding
the supernatant, the microsomal pellet was resuspended in polyethyl-
ene-glycol-free MOPS-KCl buﬀer [21]. The microsomal fraction was
enriched in ER-speciﬁc proteins (calnexin, IP3R3, SERCA2b) as re-
vealed by Western blotting (data not shown).2.3. Western blot
Microsomal proteins were loaded on polyacrylamide gels and blot-
ted on nitrocellulose. Immunoblots were probed with a rabbit poly-
clonal antiserum against the lactonase domain (residues 539-791) of
human H6PDH kindly provided by Dr. E. van Schaftingen (ICP,
Bruxelles, Belgium), or with rabbit polyclonal antibodies to mouse
11bHSD1 (Alpha Diagnostic International). After reacting with the
secondary antibodies, blots were analyzed either by enhanced chemilu-
minescence or using ﬂuorescent secondary antibodies (Amersham Bio-
sciences). The blots were visualized by Typhoon 8600 multiimager
(Amersham Biosciences).2.4. RT-PCR
PMN RNA was isolated using the RNeasy Mini Kit (Qiagen) and
human liver total RNA was from Biocat GmbH. 500 ng of RNA
was reverse transcribed by using the SuperScript II First-Strand Syn-
thesis System (Invitrogen). For H6PDH, the oligonucleotide primers
were: sense, 5 0-CAACTGGGGACCTGGCTAAGAAGT-3 0; anti-
sense, 5 0-GTTGATGAGAGGCAGGCTAAGGCT 3 0. For 11bHSD1
the oligonucleotide primers were: sense, 5 0-GAACATCAATAA
AAAGAAGTCAGA-30; antisense, 5 0-CATTATTATTACATTTC-
CATTTTG-30. PCR products were separated on a 1% agarose gel.
The identity of the RT-PCR products was conﬁrmed by DNA
sequencing.2.5. Enzyme assays
H6PDH and isocitrate dehydrogenase activities were evaluated by
measuring NADPH formation upon the addition of 1 mM NADP+
and either 10 lM glucose-6-phosphate or 1 mM isocitrate to micro-
somes. Limited access of the cofactor compounds to the intraluminal
enzymes proved the intactness of the microsomes. Microsomes have
been subsequently permeabilized with Triton X-100 (1% ﬁnal concen-
tration) to allow the free access of the cofactor to the intraluminal en-
zyme. The product of lactonase activity, 6-phosphogluconic acid, was
then measured enzymatically with 6-phosphogluconate dehydrogenase
on the basis of NADPH formation. 11bHSD1 activity was measured in
both directions, as cortisone reductase and cortisol dehydrogenase
activity, upon the addition of 100 lM NADPH or NADP+ and
20 lM cortisone or cortisol to microsomes. Microsomes have been
subsequently permeabilized with Triton X-100 (1% ﬁnal concentration)
to allow the free access of the cofactors to the intraluminal enzyme.
NADPH ﬂuorescence was monitored at 350 nm excitation and
460 nm emission wavelengths by using a Cary Eclipse ﬂuorescence
spectrophotometer (Varian).
2.6. Evaluation of apoptosis
Apoptosis was evaluated by annexin–propidium iodide staining as
described in details earlier [17].3. Results
3.1. H6PDH in microsomes of human neutrophils
H6PDH is expressed in human PMNs both at mRNA and
protein level. As shown in Fig. 1A, the analysis of RT-PCR
products showed a band whose apparent size (2094 bp) is con-
sistent with a mRNA coding for a protein of approximately90 kDa, which is the Mr of the ER H6PDH protein; human li-
ver RNA gave the same band [22]. Accordingly, in Western
blot analysis of microsomal proteins from PMNs, a band at
an apparent Mr of 90 kDa was immunorevealed by antibod-
ies towards the lactonase domain of H6PDH; this band was
also present in human (and rat) liver microsomes (Fig. 1B).
Fig. 1C shows that H6PDH activity was also present in PMN
microsomes. In the presence of NADP+, a marked G6P-depen-
dent NADPH formation was evident upon permeabilization of
the microsomal membrane (addition of Triton X-100, see ar-
row), whilst a little activity was only present before permeabili-
zation. This was expected since NADP+ cannot easily cross the
ER membrane, and indicates the predicted luminal compart-
mentation of the enzyme [22,23]. The ER H6PDH is a dual
enzyme possessing both G6P dehydrogenase and 6-phosphog-
luconolactonase activity [24]. Therefore, 6-phosphogluconolac-
tone – derived from G6P oxidation – should be further
metabolized by the same enzyme to 6-phosphogluconate. The
latter metabolite was indeed formed, as revealed by the fact that
the addition of 6-phosphogluconic acid dehydrogenase to
microsomal incubates, in which G6P has been already oxidized
to 6-phosphogluconolactone, resulted in a further increase in
NADPH level (Fig. 1C). The amount of NADPH produced
in the latter reaction (i.e., the dehydrogenation of 6-phospho-
gluconic acid) was roughly the same as NADPH amount de-
rived from G6P oxidation (see Fig. 1C). This indicates that 6-
phosphogluconate accumulates in the lumen, possibly because
the downstream enzymes of the pentose pathway are not or
poorly represented in the microsomes.
Since the presence of isocitrate dehydrogenase, another
NADPH generating enzyme was reported in liver and adipose
tissue microsomes [21], an attempt was made to demonstrate
this activity in PMN microsomes. Very low NADP+-depen-
dent latent isocitrate dehydrogenase activity was detected (less
than 5% of the observed H6PDH activity).3.2. 11bHSD1 in microsomes of human neutrophils
Not only H6PDH, but also 11bHSD1 is represented in the
ER of PMNs. The enzyme was expressed both at the mRNA
and the protein level, as shown in Fig. 2A and B, respectively.
Accordingly, 11bHSD1 activity could be also revealed in PMN
microsomes. Upon the addition of cortisone or cortisol to per-
meabilized microsomes, NADPH was consumed or NADP+
was reduced to NADPH, respectively (Fig. 2C). The activities
appeared upon permeabilization of the microsomal membrane
only. This is consistent with the luminal compartmentation of
11bHSD1 activity, as in the case of H6PDH [25,26].3.3. Cortisol prevents the proapoptotic eﬀect of the inhibition of
microsomal G6P transport in human PMNs
As we have already shown, the addition of the G6PT inhib-
itor S3483 induced apoptosis in human granulocytes (Fig. 3).
Addition of cortisol at high (20 lM) concentration did not al-
ter the rate of apoptosis. Under these circumstances 11bHSD1
presumably acts as a dehydrogenase and generates NADPH in
the ER lumen. When S3483 and cortisol were added together,
cortisol signiﬁcantly reduced the proapoptotic eﬀect of the
G6PT inhibitor. Inhibition of 11bHSD1 activity with carben-
oxolone completely abolished the preventive eﬀect of cortisol
(data not shown). Physiological cortisol concentrations (20–
100 nM) were ineﬀective. Cortisone addition did not increase
Fig. 1. Expression of H6PDH at mRNA (A) and protein (B) level and H6PDH activity (C) in human PMNs. (A) Total RNA isolated from human
neutrophils and human hepatic tissue (as a control) was reverse transcribed and subjected to PCR. A representative electrophoresis of the PCR
products (revealed with ethidium bromide) of three is shown. The ﬁrst lane (M) contains a mixture of DNA fragments of diﬀerent size (in kilobase
pairs). (B) Microsomes were prepared from human granulocytes and human or rat hepatic tissue (as controls), and microsomal proteins were
separated by 8% SDS–PAGE. Gels were blotted on a nitrocellulose membrane and the H6PDH protein was immunorevealed. The amount of
microsomal proteins (micrograms) applied was in order: rat liver 20, human liver 20, human granulocytes 20–40–80. On the left side, the size of
molecular mass markers (in kilodaltons) is shown. A representative experiment of ﬁve is shown. (C) Microsomal vesicles from human granulocytes
(0.3 mg protein/mL) were incubated in MOPS-KCl buﬀer (pH 7.2) at 37 C. H6PDH activity was evaluated by measuring NADPH formation upon
the addition of 1 mMNADP+ and 10 lM glucose-6-phosphate (G6P) to microsomes. Microsomes have been subsequently permeabilized with Triton
X-100 (T-X100, 1% ﬁnal concentration) to allow the free access of the cofactor to the intraluminal enzyme. The product of lactonase activity,
6-phosphogluconic acid, was then measured enzymatically on the basis of NADPH formation by adding 6-phosphogluconate dehydrogenase
(6PGDH). At the end of the incubation NADPH (2 lM) was added for calibration. A control experiment without G6P addition is also shown
(bottom). A representative registration from six is shown.
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concentrations (data not shown).4. Discussion
This paper demonstrates the presence of the complete
G6PT–H6PDH–11bHSD1 system in the ER of human PMNs.
Although G6PT protein and activity have been reported in our
earlier papers [17,27], H6PDH protein and activity, as well as
the occurrence of 11bHSD1 are shown for the ﬁrst time in the
ER compartment of PMNs.
The cooperation between H6PDH and 11bHSD1 based on
their co-localization and their access to a common pyridine
nucleotide pool in the ER lumen has been previously evidenced
in rat liver and adipose tissue [3,4,28,29]. A major role of the
G6PT–H6PDH–11bHSD1 triad is the prereceptorial activa-
tion of glucocorticoids, leading to metabolic eﬀects in these or-
gans and adipocyte diﬀerentiation in the latter. However, it
seems that in other cell types the system may serve other pur-
poses. The inhibition of G6PT in human and murine PMNs
[17,30] and in gliomas [31–34] causes an increased apoptosis.
The deletion of H6PDH induces skeletal myopathy with acti-
vated unfolded protein response in mice [35]. Therefore, the
missing function of both G6PT and H6PDH impairs the via-
bility of cells, possibly by altering the redox state of luminal
pyridine nucleotides in the ER/SR.Our present observations further strengthen this hypothesis.
H6PDH activity was almost completely latent in PMN micro-
somes – similarly to liver and adipose microsomes – in accor-
dance with its proposed topology, i.e. having the catalytic site
in the lumen of the ER/microsomes. Moreover, the production
of 6-phosphogluconate from G6P could be detected in PMN
microsomes, in accordance with the reported dual activity of
H6PDH possessing both G6P dehydrogenase and 6-phosphog-
luconolactonase domains. Similarly to H6PDH, 11bHSD1
activity was almost completely latent, which is again consistent
with the proposed intraluminal topology of the enzyme. The
latency of both activities is very likely due to the negligible per-
meability of the microsomal membrane to pyridine nucleotides
[3,36]. As a consequence, the concerted action of the G6PT–
H6PDH–11bHSD1 triad generates luminal NADPH and acti-
vates glucocorticoids in the granulocytes (Fig. 4A). Both the
maintenance of the reduced state of NADPH and the prerecep-
torial glucocorticoid activation (see below) can be responsible
for the antiapoptotic eﬀects. In the absence of G6PT activity –
due either to genetic or to experimental reasons – luminal
NADPH production and the consequent cortisol formation
should be impaired, which hampers the survival of the granu-
locytes (Fig. 4B). The observation that high, ‘‘metabolic’’ con-
centration of cortisol was needed in our experiments to
overcome the proapoptotic eﬀect of the G6PT inhibitor, while
low, ‘‘pharmacological’’ concentrations were ineﬀective argues
that a metabolic eﬀect rather than a direct receptor-mediated
Fig. 2. Expression of 11bHSD1 at mRNA (A) and protein (B) level
and 11bHSD1 reductase and dehydrogenase activities (C) in human
PMNs. (A) Total RNA isolated from human neutrophils and human
hepatic tissue (as a control) was reverse transcribed and subjected to
PCR. A representative electrophoresis of the PCR products (revealed
with ethidium bromide) of three is shown. The ﬁrst lane (M) contains a
mixture of DNA fragments of diﬀerent size (in kilobase pairs). (B)
Microsomes were prepared from human granulocytes and rat hepatic
tissue (as a control), and microsomal proteins were separated by 12%
SDS–PAGE. Gels were blotted on a nitrocellulose membrane and the
11bHSD1 protein was immunorevealed. The amount of microsomal
proteins (micrograms) applied was: rat liver 100, human granulocytes
100 and 200. On the left side, the size of molecular mass markers (in
kilodaltons) is shown. A representative experiment of ﬁve is shown. (C)
Microsomal vesicles from human granulocytes (0.5 mg protein/mL)
were incubated in MOPS-KCl buﬀer (pH 7.2) at 37 C. The reductase
(left panel) and dehydrogenase (right panel) activity of 11bHSD1 was
evaluated by measuring NADPH consumption/formation upon the
addition of 100 lM NADPH/NADP+ and 20 lM cortisone/cortisol to
microsomes. Microsomes have been subsequently permeabilized with
Triton X-100 (T-X100, 1% ﬁnal concentration) to allow the free access
of the cofactor to the intraluminal enzyme. At the end of the
incubation NADPH (5 or 3 lM, respectively) was added for calibra-
tion. Representative registrations from six experiments are shown.
Fig. 3. Cortisol prevents the proapoptotic eﬀect of the inhibition of
microsomal G6P transport in human PMNs. PMNs (2 · 106) were
incubated (at 37 C in 5% CO2/95% air for 60 min) in the complete
RPMI 1640 culture medium. S3483 (200 lM) and cortisol (c; 20 or
0.1 lM) were added. Cells stained with annexin reagent (to reveal
phosphatidylserine exposure on cell surface) and with propidium
iodide were observed by a real-time confocal microscope. Apoptotic
cells were identiﬁed on the basis of the phosphatidylserine exposure on
the plasma membrane surface and on morphologic changes. A
minimum of 200 cells was scored for each sample. Values are
means ± S.E.M. of 3–5 independent experiments.
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assumption is further strengthened by the blockade of the anti-
apoptotic eﬀect of cortisol by the 11bHSD1 inhibitor carben-
oxolone. On the other hand, cortisone – which can deplete
luminal NADPH [3] – was not proapoptotic even at metabolic
concentration. The possible explanation is that the relativelyhighly expressed H6PDH (Fig. 1) supported by a functioning
G6PT can maintain the reduced state of luminal pyridine
nucleotides by counterbalancing the activity of 11bHSD1
expressed at lower level (Fig. 2). The fact that cortisol added
at high concentration can prevent the proapoptotic eﬀect of
the inhibition of G6PT demonstrates the functional coopera-
tion of the G6PT–H6PDH–11bHSD1 system in the main-
tenance of the luminal NADPH pool in the ER of
granulocytes (Fig. 4C). Interestingly, a similar model has been
proposed in Leydig cells [37]. NADPH generated by the dehy-
drogenase activity of 11bHSD1 is utilized by 17bHSD3
involved in testosterone production. The cyclic reduction/
oxidation of pyridine nucleotides in the ER lumen continues
by coupling of 17bHSD3 and 11bHSD1 as long as their sub-
strates are available.
Cortisol was used as an experimental tool to demonstrate
the functioning of the G6PT–H6PDH–11bHSD1 system in
the present work; its metabolic eﬀect rather than hormonal ac-
tions were considered. However, cortisol produced by prere-
ceptorial glucocorticoid activation may have a physiological
role in the granulocytes. Locally activated glucocorticoids
can exert their eﬀects through transcriptional regulation of glu-
cocorticoid-receptor target genes or by nongenomic glucocor-
ticoid-receptor-dependent modulation of signal transduction
pathways [38]. Glucocorticoids have been recently shown to
prolong survival of human neutrophils, but the mechanisms
and implications for leukocyte signaling and homeostasis are
unclear [39–42]. The antiapoptotic eﬀect of glucocorticoids at
least in part can be exerted through the inhibition of Fas gene
expression and downstream apoptosis signaling pathways [43].
Irrespectively of the mechanism, the decreased prereceptorial
activation of glucocorticoids in the granulocytes of GSD 1b
patients adversely aﬀects the survival of these cells. Neverthe-
less, this eﬀect has not been directly proven yet, and further
work – eventually in G6PT [12] and H6PDH knockout mice
[44] – is needed to clarify this point.
Fig. 4. Maintenance of luminal NADPH in the endoplasmic reticulum promotes the survival of human neutrophil granulocytes. (A) Under
physiological conditions, intraluminal NADPH generation and glucocorticoid activation are ensured by the concerted action of the G6PT–H6PDH–
11bHSD1 system. Both the maintenance of the reduced state of NADPH and the prereceptorial glucocorticoid activation lead to antiapoptotic
eﬀects. (B) Genetic deﬁciency or experimental inhibition of G6PT (or H6PDH) impairs NADP+ reduction and cortisol production, abolishing the
antiapoptotic machinery. (C) Cortisol addition through the action of 11bHSD1 restores the antiapoptotic mechanisms.
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G6PT–H6PDH–11bHSD1 axis in human PMNs at the ﬁrst
time. The concerted action of these proteins is responsible
for the prereceptorial glucocorticoid activation, and also a ma-
jor determinant of the redox state of the NADP+/NADPH
pool in the ER lumen. This system has been widely studied
in the liver and in the adipose tissue, and its involvement in
the pathogenesis of obesity, metabolic syndrome and insulin
resistance has been proposed. Our results suggest that it also
plays a role in the modulation of apoptosis and survival of
PMNs.
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